Oral Etoposide Combined With Anlotinib in Advanced Triple Negative Breast Cancer

Inclusion Criteria: * Age between 18 and 75 year-old women; TNBC * ECOG score: 0-1, expected survival time ≥ 3months; * Pathologically or cytologically confirmed breast cancer; * Anthracycline- / taxane- pretreated (adjuvant, neoadjuvant) breast cancer patients who have failed from 1-3 standard chemotherapies after recurrence and metastasis; * According to RECIST 1.1, exist at least ≥1 measurable lesion(CT \>1cm，other examination \>2cm); * The patients have enough organ function. The laboratory test indexes must comply with the following requirements: * Blood routine: neutrophil≥1.5G/L, platelet count ≥80G/L, hemoglobin ≥90g/L * Liver function: serum bilirubin ≤ 1.5 times the upper limit of normal value; ALT and AST≤2.5 times the upper limit of normal value; ALT and AST≤5 times the upper limit of normal value when liver metastasis * Renal function: serum creatinine ≤ 1.0times the upper limit of normal value, creatinine clearance \>50ml/min（Cockcroft-Gault formula) * Women of child-bearing age should be carried out pregnancy test (serum or urine) within 7 days before recruit, the results should be negative; and are willing to adopt the appropriate methods of contraception during the trial and 8 weeks after last administration； * Can swallow oral drugs; * The patients have good compliance to the therapy and follow-up to be scheduled and are able to understand the study protocol and sign the Informed Consent Form. Exclusion Criteria: * The patients in pregnancy or lactation growth period and did not take effective contraception; * The patients who received ≥4 chemotherapies after recurrence and metastasis; involved in other clinical trials four weeks prior to the start of the study; * The patients with a variety of factors that affect the oral administration and absorption of drugs; * Prior treatment with etoposide or antiangiogenic TKI (subjects with prior use of antiangiogenic macromolecules such as bevacizumab are allowed to be enrolled); * The patients have uncontrollable mental illness； * Serous cavity effusion (such as pleural effusion and ascites) with clinical symptoms requiring clinical intervention or stable time less than 4 weeks; * The patients who had serious adverse effect to oral etoposide or were allergic to etoposide. * The patients who have only bone metastasis without other measurable lesion; * The patients experience severe cardiovascular diseases; * The patients experience severe upper gastrointestinal ulcer or malabsorption syndrome. * Abnormal bone marrow functions(neutrophil\<1.5G/L, platelet count \<75G/L, hemoglobin \<90g/L); * Abnormal renal function(serum creatinine \> 1.5 times the upper limit of normal value); * Abnormal liver function(serum bilirubin ≤ 1.5 times the upper limit of normal value); * The patients have uncontrollable brain metastasis; * Active or uncontrolled infection requiring systematic treatment (except simple urinary tract infection or upper respiratory tract infection) during the 2 weeks or 2 weeks prior to enrollment; * Previous or concurrent history of other malignant tumors.Except for the cured skin basal cell carcinoma and cervical carcinoma in situ; * The patients do have good compliance to the therapy.